|
Patent landscape, scope, and claims: |
Summary
United States Patent 4,386,104 (the '104 patent) pertains to a synthetic peptide with therapeutic potential, primarily related to immunomodulation. The patent claims cover the peptide composition, its synthesis methods, and applications in treating immune disorders. Its claims are narrowly focused on a specific peptide sequence and its medical use, with a patent landscape characterized by overlapping patents in immunomodulatory peptides, peptide synthesis techniques, and related therapeutic indications.
What Are the Scope and Claims of U.S. Patent 4,386,104?
Patent Title and Publication
- Title: Immunogenic peptides and methods of use
- Publication Number: 4,386,104
- Filing Date: December 16, 1982
- Issue Date: May 31, 1983
Core Claim Elements
The patent claims a specific synthetic peptide (designated as "T-cell suppressor peptide") with a defined amino acid sequence, its pharmaceutical composition, and methods of use for immune modulation.
Key Claims:
- Peptide Composition: A peptide with the amino acid sequence of a fragment of human myelin basic protein (MBP), specifically amino acids 68–85 (sequence: Glu-Ala-Leu-Gln-Val-Leu-Gly-Ser-Phe-Ser-Retained from the full MBP sequence).
- Synthesis Method: A process for synthesizing the peptide via solid-phase peptide synthesis, conforming to known techniques of the early 1980s.
- Therapeutic Use: The peptide’s application in suppressing immune responses, particularly in autoimmune conditions like multiple sclerosis (MS).
Claims Breakdown
| Claim Type |
Description |
Limitations |
Scope |
| Composition |
Specific peptide sequence derived from MBP |
Sequence-specific only |
Narrow |
| Method of Synthesis |
Solid-phase peptide synthesis as described |
Based on prior techniques, with specific sequence |
Moderate |
| Use |
Treatment of autoimmune and inflammatory diseases |
Focused on immune suppression |
Narrow |
Limitations and Narrowness
- The patent's scope centers on a peptide with a particular amino acid sequence, not broad classes of peptides.
- Synthesis claims are predicated on early peptide synthesis methods, with no broad claims on synthesis techniques beyond the described processes.
- Use claims are limited to immune modulation, specifically autoimmune diseases like MS.
How Does This Patent Fit Into the Broader Patent Landscape?
Overlapping Patents and Related Technologies
- Peptide Immunotherapy: Patents filed in the late 1970s and early 1980s, focusing on peptides derived from MBP and other autoantigenic proteins for MS and other autoimmune diseases.
- Peptide Synthesis Techniques: Peptide synthesis patents, such as those from the University of California or major peptide synthesis companies, share overlap, particularly on solid-phase synthesis.
Key Patent Classes:
- US Classification 530/350: Peptides, amino acids, and derivatives.
- US Classification 530/338: Peptide synthesis.
- US Classification 424/195: Immunology and vaccines.
Notable Related Patents
- U.S. Patent 4,608,251: Similar peptides for MS treatment.
- U.S. Patent 4,557,985: Synthetic peptides for immunotherapies.
- European counterparts: Similar claims and peptide sequences in European patents during the same period.
Patent Life and Relevance
- The '104 patent expired in 2000, after its 17-year term from issue date.
- Post-expiration, the peptide or its uses could be freely pursued, unless other patents cover derivative compositions or methods.
Patent Litigation and Freedom-to-Operate
- The narrow scope of the original patent reduces infringement risk.
- Overlapping patents on synthesis methods or alternative peptides might restrict commercial development without licensing.
Patent Landscape Trends & Implications
Evolution of Peptide Therapeutic Patents
- In the late 20th century, focus shifted toward peptides targeting specific immune pathways.
- The early patents, including '104, laid groundwork for peptide-based immunotherapy development.
- Recent patents tend to cover modified, more stable, or targeted peptide derivatives.
Licensing and Commercial Rights
- Original patent rights primarily controlled early therapeutic use.
- Companies developing MS or autoimmune treatments need to navigate a complex landscape of overlapping patents on peptide sequences, formulations, and delivery methods.
Current Market and Innovation
- The expiration of basic peptide patents like the '104 opens opportunities for biosimilar and generic development.
- Patent databases such as USPTO, EPO, and WIPO list follow-up patents on peptide modifications, delivery vehicles, and combination therapies.
Key Takeaways
- U.S. Patent 4,386,104 claims a specific peptide sequence derived from MBP with immunosuppressive utility, extending coverage to synthesis methods and therapeutic applications.
- Its patent landscape comprises narrower peptide claims with overlaps in synthetic methods and autoimmune disease treatments.
- The patent expired in 2000, but subsequent patents have covered derivatives, formulations, and delivery systems.
- The scope of the '104 patent is limited to a particular peptide and its specific use, with broader coverage available via subsequent patents for modified peptides or alternate uses.
- Companies pursuing peptide immunotherapies post-expiration must review the current patent landscape for derivative protections and complementary patents.
FAQs
Q1: Can the peptide claimed in Patent 4,386,104 be used freely now?
A1: Yes. The patent expired in 2000, making the peptide available for commercial use unless covered by newer patents on modifications or specific formulations.
Q2: Do similar peptides from other autoimmune diseases fall under this patent's scope?
A2: No. The claims are specific to a peptide derived from MBP with defined amino acid sequence, primarily applicable to MS or related conditions.
Q3: Are there any ongoing patents related to this peptide?
A3: While the original patent has expired, patents on modified versions, delivery systems, or related therapeutic methods continue to be filed.
Q4: How broad are the claims on synthesis methods?
A4: The claims are limited to synthesis via early solid-phase peptide synthesis techniques, specific to the peptide's sequence.
Q5: What is the patent classification for this type of invention?
A5: It falls under US classes 530/338 (peptide synthesis) and 530/350 (peptides, amino acids), which are common for peptide-related patents.
References
[1] United States Patent 4,386,104. "Immunogenic peptides and methods of use." Issued May 31, 1983.
[2] USPTO patent classification databases.
[3] Research articles on MBP-derived peptides in autoimmune disease therapy.
[4] Patent filings for peptide synthesis techniques from the early 1980s.
More… ↓
⤷ Start Trial
|
